Phase 1 · Portland area, OR
Phase 1 clinical trials in Portland area, OR
23 recruiting studies have a site in the Portland area. This page includes nearby cities such as Beaverton, Hillsboro, Gresham, Tigard.
23 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1/Phase 2
Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination
Oregon Health and Science University
- Location
- Portland, OR
- Eligibility basics
- Ages 20–49
- RecruitingHealthy volunteersEarly Phase 1
Monoferric for Prenatal Iron Deficiency
Oregon Health and Science University
- Location
- Portland, OR
- Eligibility basics
- Ages 18–65 · Women only
- RecruitingPhase 1/Phase 2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Encoded Therapeutics
- Location
- Portland, OR + 9 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 1/Phase 2
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Cabaletta Bio
- Location
- Portland, OR + 16 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 1/Phase 2
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
Boehringer Ingelheim
- Location
- Eugene, OR + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Novartis Pharmaceuticals
- Location
- Portland, OR + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 1
A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo
Teva Branded Pharmaceutical Products R&D LLC
- Location
- Portland, OR + 2 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1/Phase 2
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
Ascidian Therapeutics, Inc
- Location
- Portland, OR + 8 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 1
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Jazz Pharmaceuticals
- Location
- Portland, OR + 20 other US sites
- Eligibility basics
- Ages 12–75
- RecruitingPhase 1/Phase 2
A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)
Octant, Inc.
- Location
- Portland, OR + 1 other US site
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
CRISPR Therapeutics AG
- Location
- Portland, OR + 7 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Astellas Institute for Regenerative Medicine
- Location
- Portland, OR + 12 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 1/Phase 2
Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators
Astellas Gene Therapies
- Location
- Portland, OR + 3 other US sites
- Eligibility basics
- Up to age 3 · Men only
- RecruitingPhase 1/Phase 2
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
Alexion Pharmaceuticals, Inc.
- Location
- Portland, OR + 6 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 1
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency
Claris Biotherapeutics, Inc.
- Location
- Portland, OR + 5 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Chugai Pharmaceutical
- Location
- Portland, OR + 6 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 1/Phase 2
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
Solid Biosciences Inc.
- Location
- Portland, OR + 11 other US sites
- Eligibility basics
- Ages 0 mo–17 · Men only
- RecruitingPhase 1
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
Sonoma Biotherapeutics, Inc.
- Location
- Portland, OR + 8 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 1/Phase 2
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
AbbVie
- Location
- Portland, OR + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars
Claris Biotherapeutics, Inc.
- Location
- Portland, OR + 6 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 1/Phase 2
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
Neurona Therapeutics
- Location
- Portland, OR + 15 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1
Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings
Boulder Care
- Location
- Portland, OR
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
Splice Bio
- Location
- Portland, OR + 4 other US sites
- Eligibility basics
- Ages 12–65
Who these studies look for
Phase 1 studies often have narrow eligibility: specific age and weight ranges, no recent participation in another study, no nicotine, and limits on medications. Some Phase 1 studies recruit patients rather than healthy volunteers, so check each listing.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.